Biotech

Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers

Poster Presentations for CG-806 and APTO-253 are scheduled for December 5 th and 6 th at 2020 ASH Annual Meeting and Exposition

Aptose Biosciences Inc. ("Aptose") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update on Sunday, December 6 th at 2:00 PM PT, in conjunction with participation at the 2020 ASH Annual Meeting. The event will include the current clinical status of CG-806, Aptose's oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor currently in two Phase 1 ab trials, one in patients with relapsed or refractory acute myeloid leukemia (AML) and another in patients with relapsed or refractory B cell malignancies, as well as a review of APTO-253, a first-in-class small molecule MYC inhibitor in a Phase 1 ab trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).

Aptose Corporate Update Details

Date & Time: Sunday, December 6, 2020, 2:00 PM PT

Participant Webcast Link : http://public.viavid.com/index.php?id=142523

Participant Dial-in:

Toll Free:

Toll/International :

Conference ID:
1-877-407-9039

1-201-689-8470

13713479

The slides will be available on Aptose's website here and a recording of the presentation will be archived shortly after the conclusion of the event.

As announced previously, early clinical data, along with certain preclinical data for CG-806 and APTO-253, will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, being held virtually Saturday, December 5 – Monday, December 7, 2020. The posters will be available on the presentations page of Aptose website here .

Poster Presentation Details

Abstract #1042: A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS
Poster Session D ate & Time: Saturday, December 5, 2020, 7:00 AM - 3:30 PM PT
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I

Abstract #1174 : Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models
Poster Session Date & Time: Saturday, December 5, 2020, 7:00 AM - 3:30 PM PT
Session Name: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I

Abstract #2228 : A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Poster Session Date & Time: Sunday, December 6, 2020, 7:00 AM - 3:30 PM PT
Session Name: 642. CLL: Therapy, excluding Transplantation: Poster II

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).

For further information, please contact:

Aptose Biosciences Inc.
Greg Chow
Executive Vice President, CFO
858-926-2730
gchow@aptose.com

SMP Communications
Susan Pietropaolo
201-923-2049
susan@smpcommunications.com
LifeSci Advisors, LLC
Dan Ferry, Managing Director
617-430-7576
Daniel@LifeSciAdvisors.com

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines

- Public-Private Effort to Shift Traditional Model of Hepatitis Management to Primary Care and Help to Expand Care to More People in Need -

Gilead Sciences, Inc. today announced a new public-private initiative with the Partnership for Health Advancement in Vietnam (HAIVN), a collaboration between Brigham and Women's Hospital, Harvard Medical School and Beth Israel Deaconess Medical Center. This multi-year initiative will have a phased approach to help address barriers that limit viral hepatitis diagnosis and care at primary healthcare facilities in Vietnam and the Philippines, two countries with high burdens of hepatitis B and C.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

The Forces of Beauty® Report from The DREAM Initiative® Reveals Demand for New Standards of Beauty and Imagery

--Initiative Creates Groundbreaking New, Royalty Free Inclusive Image Gallery In Strategic Partnership with Shutterstock Studios--

Today, Allergan Aesthetics, an ABBVie company (NYSE: ABBV), and skinbetter science ® announce a new report from their DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative ® along with a long-term partnership with Shutterstock Studios. The report, titled Forces of Beauty ® provides a new understanding of what inclusive and representative beauty looks like today by shedding light on how narrowly defined Eurocentric ideals continue to impact women of color. By surveying over 4,000 women aged 21-65, from multiple geographic locations and backgrounds, the report explores what defines beauty, how beauty impacts women's lives, and the interplay between beauty and race. Some key insights include:

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
The Gummy Project Expands in US After Receiving Purchase Order from 5-Star Luxury Four Seasons Hotel San Francisco to Become Supplier of Gummy Products for Guest Room Mini-Bars

The Gummy Project Expands in US After Receiving Purchase Order from 5-Star Luxury Four Seasons Hotel San Francisco to Become Supplier of Gummy Products for Guest Room Mini-Bars

  • The Gummy Project's Peachy Bees and Watermelon Sharks expected to be featured for sale in all 277 guest rooms at the 5-star luxury Four Seasons Hotel San Francisco
  • Purchase order from world class hotel marks the achievement of another milestone in The Gummy Project's ongoing multi-channel sales strategy

The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") is pleased to announce that it has received a purchase order from the 5-star luxury Four Seasons Hotel San Francisco to become a supplier of gummies for each of the hotel's 277 guest room mini-bars.

"We are thrilled to continue our strategic expansion in the US and honoured to have been selected by the luxury 5-star Four Seasons Hotel San Francisco to be a supplier of Peachy Bees and Watermelon sharks for hotel guest rooms," said Charlie Lamb, President & CEO of GUMY. "We very much look forward to developing a long-term relationship with The Four Seasons Hotel San Francisco, who not only are a world class hotel but who also share our commitment to a more sustainable future for everyone."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Komo Plant Based Foods Expands Distribution through Quality Foods Grocery Chain

Komo Plant Based Foods Expands Distribution through Quality Foods Grocery Chain

Komo Plant Based Foods Inc. (CSE:YUM) (OTCQB:KOMOF) (FRA:9HB) ("Komo") is pleased to announce Quality Foods will be carrying Komo's 2 serving Lasagna, Shepherd's Pie and Mac & Greens as well as both Meal Helpers (Bolognese and Taco Filling) at all Quality Foods locations

Quality Foods is a British Columbia owned, award-winning leader in the Canadian grocery industry with brick and mortar stores in 13 locations in B.C. including Qualicum Foods in Qualicam Beach, Quality Foods in Parksville, Nanoose Bay, Nanaimo (Harewood), Nanaimo (Northridge Village), Port Alberni, Comox, Courtenay, Campbell River, Powell River, Victoria (Langford) and Victoria (View Royal).

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Gilead Sciences Completes Acquisition of MiroBio

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for approximately $405 million in cash. The acquisition provides Gilead with MiroBio's proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio's lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical trials, with the first patient dosed in early August 2022. MB272 targets T, B and dendritic cells to inhibit or blunt activation and suppress an inflammatory immune response.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology Convergence 2022

Five abstracts underscore the long-term safety and efficacy of voclosporin, including in Latino patients and patients with Class V lupus nephritis

Data presentation on pre-clinical asset AUR200 reinforces Aurinia's commitment to autoimmune disease

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×